Tango Therapeutics

Before heading out for the Thanksgiving holiday, we came together for our annual Tango tradition – Thanksgiving potluck! Through diverse cuisines and desserts, we learned more about the special traditions and cultures that our associates share with their family and friends every year. We wish everyone a restful and happy Thanksgiving holiday!

Meet one of the newest members of the Tango team, Maeve Waldron-Lynch, M.D., MRCP (UK), who joins in the new role of Senior Vice President, Head of Clinical Development. Maeve is a medical oncologist/hematologist with over 13 years of clinical development experience in the pharmaceutical and biotech industry in both early and late-stage development oncology, including roles at Roche, Novartis and most recently Morphosys.?At Tango, Maeve will lead our clinical development functions. Read more here: https://lnkd.in/ehSzUsPP

November is Pancreatic Cancer Awareness Month, a cause near to the hearts of everyone at Tango. As part of recognizing the month, we came together in a sea of purple to hear about the latest developments (outside of our own work at Tango) to advance potential treatments. We were joined by the family of our dear colleague and friend Dimitris Papoutsakis, who succumbed to advanced pancreatic cancer in 2021. It’s become an annual tradition for his family to join us to preserve his legacy and to support work to advance new treatments. His short yet powerful fight underscores our sense of urgency to bring new and promising treatments to cancer patients. Learn more about our work and join us: https://www.tangotx.com/ #pancreaticcancer #pancreaticcancerawareness #pancreaticcancerawarenessmonth

Meet Ajit Suri, VP of Clinical Pharmacology. Ajit brings more than 25 years of experience to Tango where he supports studies of our clinical trials to understand safety and efficacy. His work examines how our precision oncology treatments may interact with other drugs, food and how they work in different populations. The data are crucial to continuing to develop and advance these promising treatments, potentially expanding the number of people who could benefit.

Today we announced positive clinical data from the phase 1/2 clinical trial of TNG462 and an update on our PRMT5 development program. Data from the ongoing TNG462 trial demonstrate?durable clinical activity across multiple tumor types, including pancreatic and non-small cell lung cancers. We are moving to full development, with multiple?combination studies planned in 2025.?Read more here:?https://lnkd.in/dxuGQ2cS

If you’ve got it, haunt it! Last week, associates came together for our annual Tango Halloween costume contest. And they brought their creativity, Boston humor and corporate puns to life through some amazing costumes! Congrats?to the winners: Tom Garafalo as Boston’s iconic Rainbow Squash gas tank; Jeff (JP) Pagliei as Cyber Monk; Corey Kelly, MBA as legendary Mike Ditka; Ben-Oni Jean-Pierre as cloud storage and the best group costume went to Simon Liang, Katherine L., Iga Sienczylo, Margaret Wyman and Tram Anh Tran as the Tango “cat herders."

“The fact that the pharmaceutical and biotech industries exist and that you are all here to support and work in it, I think there is probably no nobler scientific pursuit, perhaps other than practicing medicine. And what we are all doing in the biotech industry is enabling that whole practice of medicine to happen.” Well said by our SVP of Chemistry, John Maxwell, as he kicked off a teach-in titled “the path to making a new medicine” at our all-company Town Hall. We reflected on the incredible journey that takes place from discovering a new molecule, to receiving FDA approval for human study. It’s astounding to recognize the work, teams and expertise required to discover a new medicine, but equally astounding to envision the potential impact for patients.?

We’re excited to see new research on STK11/KEAP1 mutations driving PD-(L)1 inhibitor resistance published in Nature, relevant to our work on TNG260. Scientists at Tango contributed in vivo functional genomics data supporting the clinical observation that the loss of the tumor suppressor genes STK11 and KEAP1 lead to cancer immune evasion and resistance to PD-(L)1 inhibitor treatment. Another direct outcome of this work was the identification of CoREST as a therapeutic target for this patient population, the target of TNG260, currently being evaluated in a phase 1/2 clinical trial (NCT05887492) This work demonstrates the urgent need for non-squamous NSCLC patients with STK11 and/or KEAP1 mutations that are refractory to PD-(L)1 inhibition, and we’re proud to be part of the broader scientific community advancing novel therapeutic strategies for these patients. Congratulations to all co-authors, and especially to Dr. Skoulidis and Dr. Heymac at MD Anderson Cancer Center for championing this multi-institutional publication integrating preclinical and clinical data from leading universities, clinical institutions and industry.

Associates cheered on colleagues (while enjoying German-themed food and beer, of course) during our annual steinholding competition celebrating Oktoberfest. Our internal events team, Movers and Shakers, organizes events like this year-round to bring together associates, celebrate our culture (and respective cultures) and often times, engage in healthy competition. Congrats to winners Tenzing Khendu and Sean Hetherman, who earned bragging rights for a year!

Two hours spent, 30 bikes built and limitless opportunities for the adventures children around Roxbury and Dorchester will be able to undertake with their new wheels. At this year’s community service day, we proudly partnered with Project HOPE Boston to support their mission of empowering women and families up and out of poverty.